Head of BioProcess Development
David joined Tessera in 2021 as the Head of BioProcess Development. He leads a team of scientists and engineers for the process development, material production and analytical analysis of DNA, RNA, LNP, AAV.
David has over 25 years of bioprocess development for a range therapeutics including novel mAbs, peptides, anti infectives, biocatalysts and more recently cell and gene therapies. During his career at Merck & Co. Inc, David led early and late stage CMC teams, providing contributions to multiple IND's & BLA's for Biologics & Vaccines. David also led an innovation team that codeveloped the state of the art ambr250 high throughput bioreactor system and also pioneered ‘lights out’ automated continuous mAb production. More recently David pursued processing for personalized neoantigen Tcell therapies and helped create corporate research for the technology provider Sartorius. David is excited to join Tessera to drive digital workflows and high throughput automation to accelerate sustainable gene therapy process development.